Tag Archive > Cancer Cases

EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans

——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/molecular diagnostics 09.12.2011 Berlin, Germany, December 9, 2011 – Epigenomics AG (ISIN: DE000A1K0516) reports the completion of the clinical validation study [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Conference Call Scheduled for today, 9thDecember 2011 at 4 pm CET Berlin, Germany, and Seattle, WA, U.S.A., December 9, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Epigenomics’ Licensee ARUP Presents Clinical Data for Colorectal Cancer Blood Test at AMP

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Company Information/molecular diagnostics Subtitle: Epigenomics to host a corporate workshop on advances in blood-based colorectal cancer screening; ARUP Laboratories will present independent data for its laboratory-developed Septin9 test Grapevine, TX, U.S.A., November 16, 2011 (euro [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Epigenomics AG reports EpiproColon® 2.0 finds 95% of cancers in clinical study

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Study provides clinical evidence for CE-marking in Europe and paves way to US pivotal clinical trial for submission to FDA before year-end Berlin, Germany, and Seattle, WA, USA, September 19, 2011 [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Epigenomics AG: New Clinical Data for Septin9 Colorectal Cancer Blood Test Presented at UEGW

Independent validation of laboratory test used in PRESEPT Study shows that the test finds 86% of the cancers ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Independent validation of laboratory test used in PRESEPT Study shows that the test finds [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Epigenomics’ Licensee ARUP Reports Excellent Validation Results for Septin9 Colorectal Cancer Blood Test

Presentation at ASCO – NCI – EORTC Molecular Markers Meeting ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/Molecular diagnostics Subtitle: Presentation at ASCO – NCI – EORTC Molecular Markers Meeting Berlin and Seattle – October 20, 2010 (euro adhoc) – Epigenomics AG’s [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Epigenomics AG: PRESEPT Study Subject Enrollment Successfully Completed

7,852 subjects prospectively enrolled including more than 50 cancer cases Blood samples selected for testing by independent biostatistics group Septin9 testing in three independent laboratories on track; majority of samples tested Completion of PRESEPT Study and reporting of top-line results expected for early 2010 ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-News: Epigenomics AG Initiates Testing of Blood Plasma Samples from PRESEPT Study in Three Independent Clinical Laboratories

PRESEPT Study evaluates clinical performance and health economic benefit of colorectal cancer screening with mSEPT9 blood test Quest Diagnostics, ARUP Laboratories, and Charité – Universitätsmedizin Berlin selected to test mSEPT9 biomarker in blood plasma samples from PRESEPT Study subjects Laboratories to use recently launched Epi proColon CE Marked IVD test products for the testing of [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,

EANS-Adhoc: Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act) Epigenomics AG Launches Colorectal Cancer Blood Test Epi proColon in Europe

——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics 06.10.2009 Epigenomics AG (ISIN: DE000A0BVT96), a cancer molecular diagnostics company, today announced, that it launched in Europe a CE-marked, [...]

Continue reading

, , , , , , , , , , , , , , , , , , ,